In the wake of the April announcement that Pfizer and Allergan called off their planned merger, Kalorama Information believes Pfizer will turn its attention back to the vaccines market.
Why? According to Kalorama’s new study, Vaccines 2016: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments, Pfizer is the world’s largest paediatric vaccine company and has good success recently with its Prevnar 13 vaccine.
The global market for human vaccines experienced strong growth through 2015, Kalorama found. Through 2022, growth will be fuelled by continued new product introductions, indication expansions for some products and rising usage, particularly in South America, Europe, India and China.
This report provides solid estimates and forecasts by category of vaccine. Estimates are provided for the 2013 to 2017 period and forecasts are provided through 2022.
Kalorama’s unique report contains detailed market coverage of the adult and pediatric vaccine market (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, et al.), including company profiles, market sizing and forecasting.